358 patents
Page 7 of 18
Utility
Modified compounds and uses thereof
17 May 22
The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications.
Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
Filed: 12 Feb 19
Utility
Methods of Treating Breast Cancer
12 May 22
Provided herein are methods, compounds, and compositions for reducing expression of a MaTAR in an animal.
David L. Spector, Sarah Daniela Diermeier, Frank Rigo, C. Frank Bennett, Susan M. Freier, Gayatri Arun, Kung-Chi Chang
Filed: 15 Jun 21
Utility
Modulating apolipoprotein (a) expression
3 May 22
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a).
Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
Filed: 30 Dec 19
Utility
Modulators of diacyglycerol acyltransferase 2 (DGAT2)
26 Apr 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting DGAT2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DGAT2.
Sanjay Bhanot, Susan M. Freier, Eric E. Swayze
Filed: 28 Jun 19
Utility
Compositions and methods for modulating growth hormone receptor expression
26 Apr 22
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
Filed: 4 Aug 20
Utility
Compounds and Methods for Reducing PMP22 Expression
14 Apr 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PMP22 RNA in a cell or animal, and in certain instances reducing the amount of PMP22 protein in a cell or animal.
Huynh-Hoa Bui, Susan M. Freier, Hien Thuy Zhao, Priyam Singh
Filed: 20 Dec 19
Utility
Modulation of GYS1 Expression
14 Apr 22
Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual.
Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
Filed: 23 Dec 21
Utility
Compositions and methods for modulating Ataxin 3 expression
5 Apr 22
Disclosed are methods for modulating splicing of Ataxin 3 mRNA in an animal with modified oligonucleotides.
Frank Rigo, Thazha P. Prakash, Wilhelmina Maria Clasina Van Roon-Mom, Lodewijk Julius Anton Toonen
Filed: 26 Nov 19
Utility
Modulators of MALAT1 expression
22 Mar 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting MALAT1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with MALAT1.
Susan M. Freier, Youngsoo Kim, Robert MacLeod
Filed: 27 Feb 20
Utility
Compounds and Methods for Use in Dystrophin Transcript
17 Mar 22
Provided herein are methods, compounds, and compositions for modulation of dystrophin pre-mRNA in an animal.
Frank Rigo, Thazha P. Prakash, Punit P. Seth
Filed: 18 Nov 20
Utility
Methods and Compositions for Modulating ALPHA-1-ANTITRYPSIN Expression
10 Mar 22
Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis.
Brett P. Monia, Michael L. McCaleb, Susan M. Freier, Shuling Guo
Filed: 13 Oct 20
Utility
Compounds and Methods for Modulation of SMN2
10 Mar 22
Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2.
Frank Rigo, Thazha P. Prakash, Punit P. Seth
Filed: 18 Dec 20
Utility
Compositions and Methods for Treating and Preventing Amyotrophic Lateral Sclerosis
10 Mar 22
Dosage regimens for SOD1-targeting antisense oligonucleotides, and salts thereof, are provided.
Ivan Alexandrov Nestorov, Toby Ferguson, Daniel A. Norris
Filed: 12 Dec 19
Utility
5′ modified nucleosides and oligomeric compounds prepared therefrom
8 Mar 22
The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 30 Apr 20
Utility
Modified Oligomeric Compounds and Uses Thereof
3 Mar 22
The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside.
Punit P. Seth, Michael T. Migawa, Graeme C. Freestone
Filed: 4 Oct 19
Utility
Compounds and Methods for Reducing ATXN3 Expression
3 Mar 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal.
Susan M. Freier
Filed: 9 May 19
Utility
Compounds and Methods for Modulating SMN2
3 Mar 22
Provided are compounds, methods, and pharmaceutical compositions for modulating SMN2 RNA and/or protein in a cell or subject.
Frank Rigo, Thazha P. Prakash, Kar Yun Karen Ling, W. Brad Wan, William John Drury, III
Filed: 26 Feb 21
Utility
Compounds and Methods for Reducing ATXN2 Expression
3 Mar 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN2 RNA in a cell or animal, and in certain instances reducing the amount of Ataxin-2 protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease.
Susan M. Freier, Priyam Singh, Frank Rigo, Paymaan Jafar-nejad, Holly Kordasiewicz
Filed: 23 Apr 21
Utility
Modulation of Hepatitis B Virus (HBV) Expression
3 Mar 22
Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression.
Eric E. SWAYZE, Susan M. Freier, Michael L. McCaleb
Filed: 30 Jul 21
Utility
Compounds and methods for modulating C90RF72
1 Mar 22
Disclosed herein are compounds and methods for modulating C9orf72 transcript.
Thazha P. Prakash, Frank Rigo, David Corey
Filed: 2 Nov 16